All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 3788
CLEAR LABELS Act

Lobbying activity 4

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. Issues related to the Most Favored Nation drug pricing.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act.

Monitored issues related to intellectual property.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.